Skip Navigation LinksHome > Advocacy > Statements

Statements

This section contains statements that have been released by AABB, its task forces or the entire blood community on issues relating to transfusion medicine and cellular therapies. Click on a link below to read current statements.

2020

Statement by AABB CEO, Debra S. BenAvram, FASAE, CAE, on COVID-19 Convalescent Plasma (CCP) – 07/30/20
Joint Statement on the Blood Supply – 5/28/20
Joint Statement on Blood Community Uniting to Support COVID-19 Patients - 4/6/20
Joint Comments to the Tick-Borne Disease Working Group with Recommendations to Inform Evidence-Based Policies – 1/24/2020 

2019

Joint Statement Before BPAC on Cold Stored Platelets for Transfusion – 11/22/19

2018

Joint Statement on Tolerable Risk in Blood Safety: Submitted to the Advisory Committee on Blood and Tissue Safety and Availability – 9/13/18
Joint Statement Before BPAC on Strategies to Control the Risk of Bacterial Contamination in Platelets for Transfusion - 7/18/18
Statement Submitted to the Assistant Secretary for Preparedness and Response on Establishing a Public-Private Partnership - 1/10/18

2017

Joint Statement Before BPAC on August 2016 Zika Guidance Document – 12/1/17
Statement on Iron Management in Blood Donors - 5/17/17
Statement Before BPAC on “Blood Donor Deferral Policy for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products” - 4/4/17

2016

Joint Statement on FDA MSM Deferral Policy - 12/16/16
Statement to ACBTSA on the RAND Report Related to the Sustainability of the U.S. Blood Supply - 11/28/16
Joint Statement Before BPAC on FDA “Recommendation for Donor Screening, Deferral and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus,” August 2016 Guidance - 11/18/16
Statement Before BPAC on the Management of Iron Deficiency Associated with Blood Donation - 11/17/16
Joint Statement Addressing Outpouring of Support from Blood Donors - 6/13/16

2015

Joint Statement on FDA Final Guidance for MSM Deferral Policy - 12/21/15
Joint Statement on Phasing-In RHD Genotyping for Pregnant Women and Other Females of Childbearing Potential with a Serologic Weak D Phenotype - 7/22/15
Statement Before BPAC on Strategies for Implementation of Testing for Babesia microti in Blood Donors - 5/13/15
Joint Statement on FDA Draft Guidance for Deferral Criteria for MSM - 5/12/15

2014

Joint Statement on FDA Recommendation to Change MSM Deferral Policy - 12/24/14
Joint Statement on ACBTSA Recommendation to Change MSM Deferral Policy - 11/14/14
Joint Statement Regarding National Gay Blood Drive - 6/26/14

2013

Joint Statement Regarding "National Gay Blood Drive" - 6/26/13